Alzamend Neuro Stock EBITDA
| ALZN Stock | USD 1.30 0.04 3.17% |
Alzamend Neuro fundamentals help investors to digest information that contributes to Alzamend Neuro's financial success or failures. It also enables traders to predict the movement of Alzamend Stock. The fundamental analysis module provides a way to measure Alzamend Neuro's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alzamend Neuro stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -9.9 M | -10.4 M |
Alzamend | EBITDA |
Alzamend Neuro Company EBITDA Analysis
Alzamend Neuro's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Alzamend Neuro EBITDA | (9.89 M) |
Most of Alzamend Neuro's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alzamend Neuro is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alzamend EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Alzamend Neuro is extremely important. It helps to project a fair market value of Alzamend Stock properly, considering its historical fundamentals such as EBITDA. Since Alzamend Neuro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alzamend Neuro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alzamend Neuro's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Alzamend Ebitda
According to the company disclosure, Alzamend Neuro reported earnings before interest,tax, depreciation and amortization of (9.89 Million). This is 101.13% lower than that of the Biotechnology sector and 109.87% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.25% higher than that of the company.
Alzamend EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alzamend Neuro's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alzamend Neuro could also be used in its relative valuation, which is a method of valuing Alzamend Neuro by comparing valuation metrics of similar companies.Alzamend Neuro is currently under evaluation in ebitda category among its peers.
Alzamend Neuro Institutional Holders
Institutional Holdings refers to the ownership stake in Alzamend Neuro that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alzamend Neuro's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alzamend Neuro's value.| Shares | Bb&t Corp. | 2024-09-30 | 15.5 K | Parallel Advisors, Llc | 2024-06-30 | 33.0 | Harbor Investment Advisory, Llc | 2024-09-30 | 20.0 | Rfg Advisory Group, Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 |
Alzamend Fundamentals
| Return On Equity | -44.08 | ||||
| Return On Asset | -2.14 | ||||
| Current Valuation | 5.74 M | ||||
| Shares Outstanding | 4.48 M | ||||
| Shares Owned By Insiders | 4.55 % | ||||
| Shares Owned By Institutions | 0.94 % | ||||
| Number Of Shares Shorted | 144.26 K | ||||
| Price To Book | 7.23 X | ||||
| EBITDA | (9.89 M) | ||||
| Net Income | (9.95 M) | ||||
| Cash And Equivalents | 11.53 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 300.71 K | ||||
| Current Ratio | 11.78 X | ||||
| Book Value Per Share | (1.41) X | ||||
| Cash Flow From Operations | (8.27 M) | ||||
| Short Ratio | 0.54 X | ||||
| Earnings Per Share | (142.87) X | ||||
| Target Price | 35.0 | ||||
| Beta | -0.038 | ||||
| Market Capitalization | 5.82 M | ||||
| Total Asset | 631.59 K | ||||
| Retained Earnings | (54.02 M) | ||||
| Working Capital | (2.77 M) | ||||
| Net Asset | 631.59 K |
About Alzamend Neuro Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alzamend Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alzamend Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alzamend Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alzamend Neuro
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.Moving against Alzamend Stock
| 0.8 | GILD | Gilead Sciences | PairCorr |
| 0.78 | BHC | Bausch Health Companies | PairCorr |
| 0.77 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.76 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.67 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Alzamend Neuro Piotroski F Score and Alzamend Neuro Altman Z Score analysis. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.